estazolam

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	4 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.10 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	93 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Property	Description	Value
kinase-safety-class	ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,MAPKAPK2,PDK4,PIK3CB,PIK3CG,PRKDC,STK33,TTK	20
kinase-selectivity-class	GRK2	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Serotonin syndrome	118.06	22.80	46	3177	37841	90587383
Drug interaction	89.95	22.80	76	3147	276377	90348847
Suicide attempt	76.48	22.80	42	3181	75357	90549867
Intentional overdose	65.41	22.80	41	3182	93793	90531431
Disease risk factor	53.63	22.80	9	3214	232	90624992
Bradycardia	49.45	22.80	33	3190	83814	90541410
Electrocardiogram QT prolonged	48.81	22.80	31	3192	72425	90552799
Sopor	46.65	22.80	21	3202	24623	90600601
Ventricular arrhythmia	44.87	22.80	13	3210	4308	90620916
Drug-disease interaction	41.31	22.80	9	3214	941	90624283
Drug dependence	37.24	22.80	19	3204	29308	90595916
Somnolence	36.61	22.80	41	3182	209043	90416181
Disseminated intravascular coagulation	36.50	22.80	17	3206	21521	90603703
Arrhythmia	35.91	22.80	21	3202	42311	90582913
Toxicity to various agents	33.56	22.80	46	3177	287800	90337424
Procedural hypotension	31.63	22.80	8	3215	1592	90623632
Electrocardiogram QRS complex prolonged	30.42	22.80	11	3212	7337	90617887
Drug abuse	29.48	22.80	24	3199	82323	90542901
Cardiac failure	27.34	22.80	26	3197	109470	90515754
Overdose	26.01	22.80	30	3193	157679	90467545
Depressed level of consciousness	25.60	22.80	21	3202	72763	90552461
Poverty of speech	25.32	22.80	5	3218	323	90624901
Rhabdomyolysis	25.08	22.80	18	3205	51238	90573986
Altered state of consciousness	25.05	22.80	15	3208	31517	90593707
Coma	23.57	22.80	20	3203	72612	90552612
Delusion of reference	22.94	22.80	4	3219	130	90625094
Circulatory collapse	22.83	22.80	13	3210	24891	90600333

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Inappropriate antidiuretic hormone secretion	51.94	23.18	22	2028	16519	42602766
Altered state of consciousness	42.78	23.18	23	2027	29236	42590049
Delirium	32.67	23.18	24	2026	52495	42566790
Hyperammonaemia	26.47	23.18	11	2039	7855	42611430
Drug interaction	25.81	23.18	46	2004	266953	42352332
Paraneoplastic syndrome	24.30	23.18	6	2044	800	42618485
Substance use disorder	23.28	23.18	9	2041	5336	42613949

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	92.88	20.44	118	5295	500065	110083821
Serotonin syndrome	76.06	20.44	43	5370	59110	110524776
Suicide attempt	67.48	20.44	49	5364	103345	110480541
Intentional overdose	62.93	20.44	52	5361	132449	110451437
Altered state of consciousness	56.06	20.44	35	5378	57591	110526295
Disease risk factor	49.60	20.44	9	5404	265	110583621
Inappropriate antidiuretic hormone secretion	47.29	20.44	26	5387	33825	110550061
Drug dependence	42.74	20.44	28	5385	49992	110533894
Electrocardiogram QT prolonged	42.05	20.44	38	5375	108922	110474964
Delirium	40.55	20.44	41	5372	134984	110448902
Coma	37.62	20.44	37	5376	117832	110466054
Rhabdomyolysis	36.96	20.44	37	5376	120364	110463522
Overdose	36.80	20.44	51	5362	233743	110350143
Persecutory delusion	35.98	20.44	13	5400	6278	110577608
Somnolence	35.52	20.44	57	5356	297392	110286494
Drug-disease interaction	32.09	20.44	9	5404	1927	110581959
Sopor	30.10	20.44	20	5393	36526	110547360
Ventricular arrhythmia	30.03	20.44	13	5400	10074	110573812
Toxicity to various agents	27.89	20.44	68	5345	480487	110103399
Hyperammonaemia	26.20	20.44	13	5400	13719	110570167
Bradycardia	26.08	20.44	35	5378	155482	110428404
Procedural hypotension	25.55	20.44	8	5405	2497	110581389
Loss of consciousness	25.32	20.44	39	5374	196267	110387619
Blood creatine phosphokinase increased	25.30	20.44	24	5389	73053	110510833
Hepatic function abnormal	24.78	20.44	26	5387	89269	110494617
Hyperthermia	23.44	20.44	14	5399	21258	110562628
Disseminated intravascular coagulation	23.41	20.44	18	5395	41268	110542618
Depressed level of consciousness	23.13	20.44	28	5385	112250	110471636
Neutrophil count decreased	23.05	20.44	29	5384	120912	110462974
Sudden death	21.67	20.44	14	5399	24381	110559505
Paraneoplastic syndrome	21.16	20.44	6	5407	1336	110582550
Electrocardiogram QRS complex prolonged	20.98	20.44	11	5402	13010	110570876
Arrhythmia	20.64	20.44	21	5392	69554	110514332
Miosis	20.48	20.44	13	5400	21970	110561916

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

estazolam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Source	Code	Description
ATC	N05CD04	NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Benzodiazepine derivatives
FDA CS	M0002356	Benzodiazepines
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018682	GABA Agents
MeSH PA	D018757	GABA Modulators
CHEBI has role	CHEBI:35474	anxiolytic drug
CHEBI has role	CHEBI:35623	anticonvulsant
CHEBI has role	CHEBI:50268	GABA modulator
FDA EPC	N0000175694	Benzodiazepine

Disease	Relation	SNOMED_ID	DOID
Severe Insomnia	indication
Alcohol intoxication	contraindication	25702006
Depressive disorder	contraindication	35489007
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Sleep apnea	contraindication	73430006	DOID:0050847
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Severe chronic obstructive pulmonary disease	contraindication	313299006
Breastfeeding (mother)	contraindication	413712001

Target	Class	Pharos	UniProt	Action	Bioact source	MoA source
GABA-A receptor alpha-1/beta-2/gamma-2	Ion channel	P14867 P18507 P47870	GBRA1_HUMAN GBRG2_HUMAN GBRB2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-2/beta-3/gamma-2	Ion channel	P18507 P28472 P47869	GBRG2_HUMAN GBRB3_HUMAN GBRA2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-3/beta-3/gamma-2	Ion channel	P18507 P28472 P34903	GBRG2_HUMAN GBRB3_HUMAN GBRA3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	WOMBAT-PK	CHEMBL
GABA-A receptor alpha-5/beta-3/gamma-2	Ion channel	P18507 P28472 P31644	GBRG2_HUMAN GBRB3_HUMAN GBRA5_HUMAN	POSITIVE ALLOSTERIC MODULATOR	WOMBAT-PK	CHEMBL

ID	Source
4019566	VUID
N0000147666	NUI
D00311	KEGG_DRUG
4019566	VANDF
C0014892	UMLSCUI
CHEBI:4858	CHEBI
CHEMBL285674	ChEMBL_ID
DB01215	DRUGBANK_ID
D004949	MESH_DESCRIPTOR_UI
3261	PUBCHEM_CID
7550	IUPHAR_LIGAND_ID
3611	INN_ID
36S3EQV54C	UNII
4077	RXNORM
10202	MMSL
4682	MMSL
d00915	MMSL
003566	NDDF
371364001	SNOMEDCT_US
96235001	SNOMEDCT_US

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Estazolam	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0744	TABLET	1 mg	ORAL	ANDA	16 sections
Estazolam	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0745	TABLET	2 mg	ORAL	ANDA	16 sections
Estazolam	HUMAN PRESCRIPTION DRUG LABEL	1	21695-220	TABLET	2 mg	ORAL	ANDA	29 sections
Estazolam	Human Prescription Drug Label	1	70954-480	TABLET	1 mg	ORAL	ANDA	26 sections
Estazolam	Human Prescription Drug Label	1	70954-481	TABLET	2 mg	ORAL	ANDA	26 sections
Estazolam	HUMAN PRESCRIPTION DRUG LABEL	1	75907-028	TABLET	1 mg	ORAL	ANDA	31 sections
Estazolam	HUMAN PRESCRIPTION DRUG LABEL	1	75907-029	TABLET	2 mg	ORAL	ANDA	31 sections

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.82	Basic
pKa2	4.83	Basic